The presented economic model estimated costs and benefits of a novel in vitro diagnostic kit for infective endocarditis (IE), developed by Hutman Diagnostics AG (Basel, Switzerland). This new product applies molecular diagnostics to detect bacteria in cardiac tissue faster (see Fig. 1 ).
Bibliography
Decision tree for aetiopathology of IE As the novel kit provides results within 4-6 hours after sampling instead of 2-3 days by MCs, the following three main outcome scenarios (S) for aetiopathology of IE were investigated by establishing a decision tree: S1 -Adjusted hospitalisation and treatment: Decreased average hospitalisation and earlier specific antibiotic treatment due to quicker diagnosis. S2 -Reoperation: Reduction of reoperation frequency. S3 -Influence on mortality of recurrent and uncontrolled IE: Reduction of mortality due to fistula formation.
Statistics for decision tree
The quantitative model uses statistical data for the decision tree from literature and interviews with clinical experts.
Assumptions for Switzerland:
• Incidence of IE cases of 3.1/100'000 population and year 10 • Implication of required surgery in about 50% of all IE patients 1-3, 5, 9, 11 • Pathogen identification before surgery in about 80% of all cardiosurgery patients 6 • average operative mortality of 10% 4
In conclusion, for CH these assumptions lead for S1 to 67.1 patients on average per year with definitive IE but without diagnosis for a specific pathogen after cardiosurgery by assuming Respective figures for GER and the UK and cases in S2 and S3 are depicted in Table 1 . 7, 8, 10 These basic data allow estimating potential cost savings comparing the two diagnostic procedures for the three countries.
Economic parameters
Parameters quantified for both diagnostic procedures were following:
• Capital costs: includes additional equipment needed • Diagnostics: includes labour costs, costs for the related diagnostic method and specific required (e.g. DNA isolation) • Reoperation: costs for cardiac surgery • Antibiotics: difference in costs for empiric and specific antibiotics • Hospitalisation: difference in duration of hospitalisation • Productivity losses: costs due to absence at patients' working places • Productivity losses YLL: costs due to premature death of patients and the years of life lost (YLL)
The outcome spectra and their economic performance were transferred into potential savings due to Endocardi-Gene ® Tissue. The highest savings per patient could be generated in Switzerland for all three scenarios, followed by Germany and UK.
In S1 the relevant cost parameter for the savings due to EndocardiGene ® Tissue is the shorter hospitalisation. The main cost saving factors for all investigated countries in S2 are also mitigation of productivity losses YLL, shorter hospitalisation and avoidance of reoperation. S3 could potentially provide the highest savings due to the avoidance of premature mortality and the related productivity losses due YLL.
Potential financial and economic cost savings of up to almost 29 Mio £ (35 Mio €) in UK, 22 Mio € in GER and 3.9 Mio CHF (3.2 Mio €) in CH per year could be realised by using Endocardi-Gene ® Tissue as diagnostic procedure instead or together with the standard procedure of microbiological culture as summarized in Table 3 .
These savings are estimated based on the total amount of all three scenarios: 74 patients in CH, 770 patients in GER and about 1'612 patients in UK per year.
Due to current clinical reality and according to Duke's criteria it is assumed that Endocardi-Gene ® Tissue would not replace microbiological culturing completely, but could complement the standard diagnostic procedure and display its advantages in speed.
in CH main contributing cost factors relevant for potential savings are in the same order as follows: the mitigation of productivity losses YLL, shortage of hospitalisation and avoidance of reoperation. In GER the same order is shown for cost parameters. Furthermore, productivity losses and adapted antibiotic treatment have a financial impact yet in GER with a shared amount of about 400'000 €/a. In the UK reduction in productivity losses YLL also accounts the most for potential savings. But following avoidance of reoperation contributes the second most before shorter lengths of stay in hospital due to lower relative costs per hospital day and patient in an average UK hospital compared to GER and CH.
Additional economic benefits from earlier and more targeted treatment for different complications of IE (e.g. risk for systemic embolism) can be expected and are not taken into account in this study. Furthermore, operation and maintenance costs in more diverse outcome scenarios as well as the influence on long-term mortality could contribute to a higher level of detail and exactness.
Therefore, it is recommended to verify the assumptions and estimated potentials supplementing this study with additional data and information from pilot studies and clinical trials with Endocardi-Gene ® Tissue. The potential savings per patient and country for each scenario are presented in Table 2 in national currency as well as in Euros. 
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